OTIC News and Press, Otonomy Inc. From 08/01/22

Otonomy, Inc. (NASDAQ: OTIC) reported that the OTO-313 Phase 2 trial in tinnitus demonstrated no meaningful benefit versus placebo for primary and secondary endpoints across all timepoints.  The phase 2 trial enrolled 153 patients with unilateral, persistent tinnitus of a...

Gainers: Virax Biolabs ( VRAX ) +62% . Aethlon Medical ( AEMD ) +46% . GeoVax Labs ( GOVX ) +46% . Celyad Oncology ( CYAD ) +40% . Outset Medical ( OM ) +28% . Losers: Otonomy ( OTIC ) -77% . Kazia Therapeu...

The shares of neurology focused Otonomy ( NASDAQ: OTIC ) plunged ~73% in the pre-market Monday after the company said its Phase 2 trial for OTO-313 did not demonstrate a clinically meaningful benefit for OTO-313 compared to placebo in hearing disorder tinnitus. "These ...

Otonomy ( OTIC ) -68% reports results from Phase 2 clinical trial of OTO-313 in patients with Tinnitus. Kazia Therapeutics ( KZIA ) -47% . Senti Biosciences ( SNTI ) -18% . FaZe Holdings ( FAZE ) -17% . Beam Therapeutics ( BEAM )...

OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepoints Company to discontinue development of OTO-313 and implement other measures to extend its cash runway Clinical focus shifts to OTO-413 foll...

Image source: The Motley Fool. Otonomy (NASDAQ: OTIC) Q2 2022 Earnings Call Jul 25, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Otonomy (OTIC) Q2 2022 Earnings Call Transcript

Otonomy, Inc. (OTIC) Q2 2022 Earnings Conference Call July 25, 2022 4:30 PM ET Company Participants Robert Uhl - Managing Director, ICR Westwicke Dave Weber - Chief Executive Officer, President and Board Member Paul Cayer - Chief Financial and Business Officer ...

Otonomy press release ( NASDAQ: OTIC ): Q2 GAAP EPS of -$0.19 beats by $0.01 . Cash Position: Cash, cash equivalents, and short-term investments totaled $53.1 million as of June 30, 2022, compared to $77.4 million as of December 31, 2021. Outlook: Financial Gui...

Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line results expected in third quarter of 2022 Positive top-line results announc...

SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update ...